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of two different PFS (once a day each) to prevent sea-
sonal allergy and a recent consumption of raw fish. No 
other medical treatment was taking by the patient in 
the same period. PFS composition is reported in Table 1.
Laboratory test revealed normal blood count and 
basic metabolic panel. Liver tests showed Alanine Ami-
notransferase (ALT) level of 2605 IU/L, aspartate ami-
notransferase of 918 IU/L, and a total bilirubin of 17.35 
mg dl-1 (directed 13.44 mg dl-1) (Table 2). Both hepati-
tis B and C testing were negative.
Instrumental investigations to rule out all other 
causes of jaundice were performed. Imaging studies for 
biliary obstruction were negative. He was discharged 
with the diagnosis of “food acute hepatitis” and a bland 
diet and biliary salt therapy was provided. Symptoms 
disappeared in 3 months, with the normalization of se-
rum liver enzyme (Table 2).
One year later, in the same season, patient was 
re-admitted because of jaundice, with similar symp-
toms described before, including nausea, vomiting, 
headache, and yellow skin. On admission Alanine Ami-
notransferase (ALT) level was of 2158 IU/L and the as-
partate aminotransferase was of 924 IU/L, while total 
bilirubin was 10.12 mg dl-1 (Table 2). He reported the 
consumption of the same PFS of the previous year (PFS 
ingredients are reported in Table 1), started 10 days 
before. PFS consumption was immediately interrupted 
and the patient was treated again with a bland diet and 
biliary salt. This new episode of acute hepatitis was re-
CASE REPORT
Introduction
The use of botanicals is increasingly throughout the 
world. They are ingredients of different types of prod-
ucts, such as herbal medicinal products, Plant Food 
Supplements (PFS), and functional foods. They are 
commonly taken to promote health and treat or pre-
vent diseases, even if, in most of cases, there is no clear 
evidence of their clinical efficacy. In recent years, sev-
eral reports have highlighted the beneficial effects of 
botanicals or PFS in the prevention of some chronic dis-
eases [1,2]. But these positive effects are accompanied 
by the increased incidence of hepatic damage caused 
by herbal medicines, including PFS [3-7]. We are pre-
senting two repeated cases of acute hepatitis occurred 
in the same patient for two consecutive years, after tak-
ing the same PFS.
Case Presentation
A 40-year-old male, healthy, with no morbidities, 
was hospitalized with nausea, vomiting, pruritus, and 
headache. Symptoms were started two days before. At 
clinical examination skin and sclera were yellow; these 
signs in association with symptoms were suggestive for 
acute hepatitis. There was no other sign of chronic liver 
disease. He reported a 14-day ongoing natural therapy 
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MS/MS analysis on the acetone extract prepared from 
the PFS capsules allowed us to exclude the presence of 
teucrin A, which is the main hepatotoxic neo-clerodane 
occurring in Germander.
Neo-clerodane diterpenoids with cytotoxic activity 
have been identified from the whole plant of Scutellaria 
spp. and from the aerial parts of Scutellaria baicalen-
sis [12], thus suggesting that these compounds, which 
effects in humans have not been still identified, could 
have toxic effects comparable to those exerted by teu-
crin A.
Although skullcap seems to be the candidate mostly 
responsible for the adverse effect, the contribution of 
other botanicals occurring in both the formulations can-
not be excluded.
Hepatotoxicity of green tea preparations, mainly con-
taining unusual concentration of catechins, has been re-
viewed [7,13]. Although the bioavailability of catechins is 
low after oral administration, plasma levels can reach tox-
ic levels under fasting or repeated administration. Green 
tea hepatotoxicity has been imputed to the capability of 
Epigallocatechin-3-O-Gallate (EGCG) or its metabolites to 
induce oxidative stress in the liver [13].
solved in further 3 months with the complete normal-
ization of serum liver enzyme. The new imaging showed 
the presence of mild steatosis.
Discussion
In this report, the etiology of the acute liver injury 
is resulted unequivocal the second year considering 
the consumption of the same PFS of the previous year. 
Identifying any toxic component(s) in herbal mixtures is 
a major problem since such supplements contain multi-
ple ingredients. Each component may not be pure com-
pounds and not all components occurring in the extracts 
could be listed as ingredients. Among all the botanicals 
present in the PFS of this case, hepatotoxic reactions 
have been reported after ingestion of Scutellaria spp. 
(skullcap)-containing preparations, alone or combined 
with other plant extracts [8,9]. Accordingly, the Food 
and Drug Administration (FDA) has listed skullcap as 
an herb of undefined safety. Moreover, some skullcap 
preparations available from wholesale suppliers contain 
species belonging to the Teucrium genus, including the 
hepatotoxic plant Germander (Teucrium chamaedrys L.) 
[10]. This observation strongly highlights the need for 
an accurate identification of the plant material [11]. LC-
Table 1: Pfs ingredients, standardization and in vivo Cyp3a4 modulation.
PFS-1 Composition* In vivo CYP3A4 
Modulation
Standardization 
of Active 
Compounds
PFS-2 
Composition#
In vivo CYP3A4 
Modulation
Standardization 
of Active 
Compounds
Ginkgo biloba L. dried 
extract from leaves
CYP3A inhibition in rats 
[16,17]; slight CYP3A 
induction in humans 
[18,19]; CYP3A4 
inhibition in humans [20]
24% Ginkgo 
flavonoids, 5% 
terpenes lattons
Perilla 
frutescens L. 
dried extract 
from leaves 
and seeds
2.5% total 
polyphenols
Schisandra chinensis 
Turcz. dried extract from 
fruits
CYP3A4 induction in rats 
[21]
5% schizandrin Scutellaria 
baicalensis 
Georgi root 
extract
Baicalin inhibits 
CYP3A4 in rats 
[22]
30% baicalein
Camellia sinensis Kuntze 
(green tea)
CYP3A inhibitor [23]; 
potent inhibitor CYP3A4 
[24,25]
95% total 
polyphenols
Citrus x 
sinensis L.
The aglycone 
of hesperidin 
(hesperetin) 
inhibitis CYP3A4 
in rats [26]
60% hesperidin
*Composition included vitamin B12 (0.1%) and DL-phosphoserine; #Composition included quercetin and maltodestrine from Zea 
mays L.
Table 2: The evolution of the liver enzymes at the first and second year.
Examination 1st case
05-07-2014
Day 15 Day 30 Day 60 Day 90 2nd case
04-28-2015
Day 30 Day 60 Day 90
Tot Bilirubin mg dl-1
Directed mg dl-1
17.35 
13.44
8.45
6.36
3.95
2.41
2.60
1.41
1.98
0.70
10.12
6.35
3.45
2.35
2.40
1.45
2.29
0.66
ALT mU/ml 2605 829 225 74 31 2158 260 80 20
AST mU/ml 918 453 196 78 15 924 170 65 18
LDH mU/ml 325 225 190 385 170
ϒGT mU/ml 157 29 188 15
ALP mU/ml 154 38 175 39
IgM Neg Neg
Hepatitis E Neg Neg
IgM Hepatitis A Neg Neg
IgG Hepatitis A Neg Neg
Chronic viral hepatitis Neg Neg
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rats. Biol Pharm Bull 26: 1315-1320. 
18. Robertson SM, Davey RT, Voell J, Formentini E, Alfaro RM, 
et al. (2008) Effect of Ginkgo biloba extract on lopinavir, 
midazolam and fexofenadine pharmacokinetics in healthy 
subjects. Curr Med Res Opin 24: 591-599. 
19. Markowitz JS, Donovan JL, Lindsay DeVane C, Sipkes L, 
Chavin KD (2003) Multiple-dose administration of Ginkgo 
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and pharmacodynamics of tolbutamide and midazolam in 
healthy volunteers. J Clin Pharmacol 46: 1290-1298.
21. Su T, Mao C, Yin F, Yu Z, Lin Y, et al. (2013) Effects of 
unprocessed versus vinegar-processed Schisandra 
chinensis on the activity and mRNA expression of CYP1A2, 
CYP2E1 and CYP3A4 enzymes in rats. J Ethnopharmacol 
146: 734-743. 
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23. Misaka S, Kawabe K, Onoue S, Werba JP, Giroli M, et al. 
(2013) Green tea extract affects the cytochrome P450 3A 
activity and pharmacokinetics of simvastatin in rats. Drug 
Metab Pharmacokinet 28: 514-518. 
Several herbal ingredients, occurring within both the 
above-mentioned PFS, have been identified as modula-
tors of various cytochrome P450 enzymes, particularly 
CYP3A4 [9]. CYP3A4 modulators could potentiate the 
intrinsic hepatotoxicity of other substances, including 
neo-clerodane diterpenoids, by an increased conversion 
to toxic metabolites. Table 1 reports the in vivo modula-
tion of cytochromes by ingredients included in PFS.
The hepatocellular (not cholestatic) injury with the 
combination of increased aminotransferase and serum 
total bilirubin could lead to consider the patient as a 
Hy’s law case [14]. Unfortunately, botanicals are not in-
cluded among Drug-Induced-Liver-Injury (DILI) [15], but 
considering symptoms and the clinical history of the pa-
tient, we cannot exclude a Hy’s law case.
The current case report suggests the potential hep-
atotoxicity of some PFS commercially available; since 
they are accessible to the public and used as self-medi-
cation, the risk of adverse effects is high. This highlights 
the need for an active surveillance on PFS to provide 
detailed information on their safety. Further, the possi-
bility of interactions among PFS ingredients before com-
mercialization should be considered as well as new data 
on the safety of neo-clerodanes in skullcap.
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